Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion (2026-06-09)
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.